Manager TitleAgeSince
President - 14/12/2023
Investor Relations Contact - -
Director TitleAgeSince
Director/Board Member 57 14/12/2023
Director/Board Member - 14/12/2023
Date Insider Type Main position Quantity % Market Cap.
14/12/23 Issuer sale

Director

127,934 0.0678%
14/12/23 Issuer sale

Chief Executive Officer

643,595 0.3411%
14/12/23 Issuer sale

Director

97,934 0.0519%
Change 5-day change 1-year change 3-year change Capi.($)
-0.07%+4.77% - - 43.15B
+1.14%+3.46%+4.57%+24.14% 50.5B
-1.33%+4.60%+484.32%+607.37% 46.01B
-2.13%+3.98%+19.67%+88.75% 42.85B
+2.78%+6.45%+33.88%+19.94% 41.03B
0.00%-3.91%+17.87%+47.98% 32.02B
+0.70%+5.29%+31.56%+149.09% 16.98B
-1.86%+3.24% - - 17.05B
+3.06%+4.63%+7.40%+35.00% 14.3B
+0.51%+3.85%+83.04%+45.38% 13.84B
Average +0.35%+2.01%+85.29%+127.20% 30.51B
Weighted average by Cap. +0.25%+2.37%+105.27%+151.36%
Logo Seagen Inc.
Seagen Inc. est spécialisé dans le développement et la commercialisation de thérapies à base d'anticorps monoclonaux destinées au traitement du cancer. Le CA par source de revenus se répartit comme suit : - ventes de produits (87%) ; - royalties (8,4%) ; - revenus issus d'accords de collaboration et de licence (4,6%).
Employees
3,256
  1. Stock Market
  2. Stocks
  3. SGEN Stock